KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.96

Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma.

Tomomi Egawa-Takata, Yutaka Ueda, Kimihiko Ito, Kensuke Hori, Shoji Tadahiro, Takayuki Nagasawa, Shin Nishio, Kimio Ushijima, Nishino Koji, Takayuki Enomoto, Akira Kikuchi, Shigeru Honma, Tetsuro Oishi, Muneaki Shimada, Yuji Takei, Hiroyuki Fujiwara, Hiroshi Tanabe, Aikou Okamoto, Yukihiro Nishio, Tomomi Yamada, Tadashi Kimura

Cancer Sci 113(5) 1693-1701

PMID35218673
PMCIDPMC9128191
DOI10.1111/cas.15310
发表日期2022-02-26
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
摘要

摘要

This study evaluated the feasibility and efficacy of three postoperative adjuvant chemotherapy regimens for endometrial cancer. Endometrioid cancer patients with intermediate-risk stage I and II or high-risk stage III and IV disease were randomly assigned to receive six cycles of either paclitaxel-epirubicin-carboplatin (TEC), paclitaxel-anthracycline (doxorubicin)-carboplatin (TAC), or dose-dense paclitaxel-carboplatin (ddTC). The primary end-point was the completion rate (CRate) of six cycles of treatment. The secondary end-points were progression-free survival (PFS) and overall survival (OS). One hundred and one patients were treated as follows: 33 received TEC, 33 TAC, and 35 ddTC. The CRates for TEC, TAC, and ddTC were 94%, 64%, and 69%, respectively (P = .005). The TEC CRate was significantly higher than for the other two groups. However, the PFS and OS outcomes were not statistically different between the three groups. The 2-year survival rates were 94%, 97%, and 97% for TEC, TAC, and ddTC, respectively. When compared to the current standard treatments for endometrial cancer, TEC is a promising candidate for a phase III trial based on its significantly superior CRate and equivalent PFS and OS. This study is registered with UMIN Clinical Trials Registry (UMIN000008911).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。